4 citations
,
August 2010 in “Acta Biologica Hungarica” This study found that novel compounds moderately inhibited 5α-reductase type 1 activity compared to finasteride, offering valuable data on structure-activity relationships.
6 citations
,
April 2014 in “European journal of medicinal chemistry” This study found that several newly synthesized dihydrobenzopyran compounds inhibited insulin secretion and had vasorelaxant activity, with some more potent than reference KATP channel activators, though compound 21 functioned as a Ca2+ entry blocker.
17 citations
,
August 2011 in “Current Medicinal Chemistry” This review summarizes recent advancements in steroidal 5α-reductase inhibitors for benign prostatic hyperplasia and reports no new clinical results.
13 citations
,
May 2011 in “Bioorganic & Medicinal Chemistry” This study identified certain benzopyran derivatives with a bulky tert-butyloxycarbonylamino group as effective KATP channel openers that inhibit insulin secretion in rat pancreatic islets.
This study explored new molecular structures as potential COVID-19 treatments, identifying a compound called Hit15 that inhibited viral infection in lab settings and reduced inflammation markers in human neutrophils, suggesting further development is warranted.